Rinvoq (upadacitinib) works by blocking a specific enzyme inside your cells called JAK1, which plays a central role in driving inflammation. Unlike biologic medications that are injected and target individual proteins outside the cell, Rinvoq is a once-daily pill that interrupts inflammatory signaling from within the cell itself. It’s FDA-approved for nine conditions, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis.
How JAK1 Drives Inflammation
To understand what Rinvoq does, it helps to know what it’s stopping. Your immune system uses chemical messengers called cytokines to coordinate its response to threats. When a cytokine docks onto a receptor on the surface of a cell, it triggers a chain reaction inside the cell. The first step in that chain is activating enzymes called Janus kinases, or JAKs. There are four types: JAK1, JAK2, JAK3, and TYK2.
Once activated, JAKs switch on proteins called STATs, which pair up and travel into the cell’s nucleus. There, they flip on genes that produce more inflammatory signals, recruit immune cells, and amplify the immune response. In autoimmune and inflammatory diseases, this signaling pathway gets stuck in overdrive, producing chronic inflammation that damages joints, skin, or the gut lining.
What Rinvoq Does Inside the Cell
Rinvoq works by physically blocking JAK1 from doing its job. It competes with a molecule called ATP, which JAKs need as fuel to activate. When Rinvoq occupies the spot where ATP would normally bind, JAK1 can’t switch on. Without active JAK1, the downstream STAT proteins never get activated, never pair up, and never reach the nucleus to turn on inflammatory genes. The entire signaling cascade stalls.
What makes Rinvoq different from older JAK inhibitors is its selectivity. In lab testing, it was over 40 times more selective for JAK1 compared to JAK2, 130 times more selective versus JAK3, and 190 times more selective versus TYK2. That selectivity matters because JAK2, for example, is involved in producing red blood cells and platelets. A drug that heavily suppresses JAK2 could cause anemia or bleeding problems. By focusing primarily on JAK1, Rinvoq aims to quiet the inflammatory pathways while leaving other functions more intact.
Conditions It Treats
Rinvoq is approved for a broad and growing list of inflammatory conditions. For most of these, it’s prescribed after a patient has already tried a TNF blocker (a type of biologic) without adequate results:
- Rheumatoid arthritis in adults
- Psoriatic arthritis in adults and children 2 and older
- Atopic dermatitis in adults and children 12 and older, when other systemic treatments haven’t worked well enough
- Ulcerative colitis in adults
- Crohn’s disease in adults
- Ankylosing spondylitis in adults
- Non-radiographic axial spondyloarthritis in adults
- Polyarticular juvenile idiopathic arthritis in patients 2 and older
- Giant cell arteritis in adults
How It’s Taken and How Quickly It Works
Rinvoq is taken as a once-daily pill. The standard dose for most conditions, including rheumatoid arthritis and psoriatic arthritis, is 15 mg. Ulcerative colitis uses a higher induction dose of 45 mg daily for the first 8 weeks, then drops to 15 mg daily for maintenance (with 30 mg as an option for more severe cases).
After you take a dose, the drug reaches its peak concentration in your blood within about 2 to 3 hours. It has a half-life of 8 to 14 hours, meaning your body clears roughly half of it within that window. Your liver breaks it down, primarily through a specific enzyme pathway. Because the drug works by blocking an ongoing signaling process rather than slowly building up antibodies (as biologics do), many patients begin to notice improvement within the first few weeks of treatment, though full benefit often takes longer to develop.
How It Compares to Biologics
In head-to-head clinical trials against adalimumab (a widely used TNF blocker), Rinvoq consistently came out ahead on key measures of disease control. In a study of rheumatoid arthritis patients who had already failed a TNF inhibitor, 43.3% of those on Rinvoq achieved low disease activity at 12 weeks, compared to 22.4% on adalimumab. Pain scores also improved significantly more with Rinvoq.
Longer-term data tells a similar story. After 5 years in the SELECT-COMPARE trial, about 31.8% of patients on Rinvoq achieved disease remission by one standard measure, compared to 23.2% on adalimumab. Physical function improvements, however, were similar between the two drugs, suggesting that while Rinvoq may control inflammation more effectively, the overall impact on daily disability can be comparable.
Safety Profile and Serious Risks
Rinvoq carries a boxed warning, the FDA’s most prominent safety alert, covering five categories of risk: serious infections, mortality, malignancies, major cardiovascular events, and blood clots. These warnings apply to the entire class of JAK inhibitors and stem partly from a large safety study of a different JAK inhibitor (tofacitinib) that found higher rates of these events compared to TNF blockers in rheumatoid arthritis patients over 50 with cardiovascular risk factors.
The infection risk is the most commonly encountered concern in practice. Because Rinvoq dampens the immune system’s inflammatory response, it also reduces your ability to fight certain infections. Reactivation of herpes zoster (shingles) and serious bacterial or fungal infections have been reported. Patients are tested for latent tuberculosis before starting treatment.
Five-year integrated safety data across psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis showed no new safety signals emerging over time. Rates of serious cardiovascular events and blood clots remained low (0.6 events or fewer per 100 patient-years) and were comparable between Rinvoq and adalimumab. Rates of serious infection were somewhat higher with Rinvoq than adalimumab in psoriatic arthritis patients, at 3.9 versus 1.6 events per 100 patient-years when including COVID-related infections. The overall mortality rate among patients on Rinvoq was not higher than what would be expected in the general population.
Higher rates of herpes zoster, certain low white blood cell counts, and non-melanoma skin cancer were also observed with Rinvoq compared to adalimumab in psoriatic arthritis trials. Current or past smokers face additional risk for both malignancies and cardiovascular events while on any JAK inhibitor.